BMS-790052 对 HCV 基因 4 型 NS5A 的体外活性。
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
机构信息
Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
出版信息
Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11. Epub 2011 Dec 27.
Abstract
The antiviral profile of BMS-790052, a potent hepatitis C virus (HCV) replication complex inhibitor targeting nonstructural protein NS5A, is well characterized for HCV genotype-1. Here, we report that BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with 50% effective concentrations (EC(50)s) ranging from 7 to 13 pM. NS5A residue 30 was an important site for BMS-790052-selected resistance in the hybrid replicons. Our results support the potential of BMS-790052 as a valuable component of combination therapy for HCV genotype-4 chronic infection.
摘要
BMS-790052 是一种针对非结构蛋白 NS5A 的强效丙型肝炎病毒 (HCV) 复制复合物抑制剂，其对 HCV 基因型-1 的抗病毒特性已得到充分描述。在这里，我们报告 BMS-790052 可抑制含有 HCV 基因型-4 NS5A 基因的杂交复制子，其 50%有效浓度 (EC(50)s) 范围为 7 至 13 pM。NS5A 残基 30 是 BMS-790052 在杂交复制子中选择耐药性的重要位点。我们的结果支持 BMS-790052 作为 HCV 基因型-4 慢性感染联合治疗有价值的组成部分的潜力。
相似文献
1
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11. Epub 2011 Dec 27.
2
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.
Antimicrob Agents Chemother. 2013 Jan;57(1):611-3. doi: 10.1128/AAC.01874-12. Epub 2012 Oct 22.
3
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.
Antimicrob Agents Chemother. 2011 Aug;55(8):3795-802. doi: 10.1128/AAC.00146-11. Epub 2011 May 16.
4
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63. doi: 10.1128/AAC.02788-14. Epub 2014 Jun 16.
5
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.
6
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
Gastroenterology. 2011 Mar;140(3):1032-42. doi: 10.1053/j.gastro.2010.11.036. Epub 2010 Nov 25.
7
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8. doi: 10.1128/AAC.05977-11. Epub 2012 Jan 3.
8
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
J Virol. 2011 Jul;85(14):7312-20. doi: 10.1128/JVI.00253-11. Epub 2011 May 18.
9
Synergistic Activity of Combined NS5A Inhibitors.
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1573-83. doi: 10.1128/AAC.02639-15.
10
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.
Hepatology. 2012 Jun;55(6):1692-9. doi: 10.1002/hep.25581.
引用本文的文献
1
Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
Infection. 2018 Dec;46(6):761-783. doi: 10.1007/s15010-018-1188-3. Epub 2018 Aug 6.
2
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Hepatol Int. 2018 Jul;12(4):348-355. doi: 10.1007/s12072-018-9868-8. Epub 2018 May 12.
3
Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview.
J Clin Transl Hepatol. 2016 Dec 28;4(4):336-344. doi: 10.14218/JCTH.2016.00038. Epub 2016 Nov 3.
4
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.
J Immunol Res. 2016;2016:1412840. doi: 10.1155/2016/1412840. Epub 2016 Oct 24.
5
Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis.
Springerplus. 2016 Sep 15;5(1):1569. doi: 10.1186/s40064-016-3218-x. eCollection 2016.
6
Direct anti-HCV agents.
Acta Pharm Sin B. 2016 Jan;6(1):26-31. doi: 10.1016/j.apsb.2015.09.008. Epub 2015 Nov 24.
7
Synergistic Activity of Combined NS5A Inhibitors.
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1573-83. doi: 10.1128/AAC.02639-15.
8
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Hepatol Int. 2016 Mar;10(2):258-66. doi: 10.1007/s12072-015-9668-3. Epub 2015 Nov 5.
9
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
J Infect Dis. 2016 Jan 15;213(2):206-15. doi: 10.1093/infdis/jiv379. Epub 2015 Jul 13.
10
Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.
Viruses. 2014 Nov 6;6(11):4227-41. doi: 10.3390/v6114227.
本文引用的文献
1
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.
2
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
Hepatology. 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.
3
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
J Virol. 2011 Jul;85(14):7312-20. doi: 10.1128/JVI.00253-11. Epub 2011 May 18.
4
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
J Hepatol. 2011 Jun;54(6):1250-62. doi: 10.1016/j.jhep.2010.11.016. Epub 2010 Dec 8.
5
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50. doi: 10.1128/AAC.00556-10. Epub 2010 Jun 28.
6
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.
7
Identification of hepatitis C virus NS5A inhibitors.
J Virol. 2010 Jan;84(1):482-91. doi: 10.1128/JVI.01360-09.
8
euHCVdb: the European hepatitis C virus database.
Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6. doi: 10.1093/nar/gkl970. Epub 2006 Nov 16.
9
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.
Antimicrob Agents Chemother. 2005 Apr;49(4):1346-53. doi: 10.1128/AAC.49.4.1346-1353.2005.
10
Genetic diversity and evolution of hepatitis C virus--15 years on.
J Gen Virol. 2004 Nov;85(Pt 11):3173-3188. doi: 10.1099/vir.0.80401-0.
Zotero 插件